Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease
Primary result · 3-point MACE (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke)Result — go to the resultHazard ratio 0.99 95% CI 0.88–1.11Authors' conclusion
Among patients with atherosclerotic cardiovascular disease, chronic kidney disease, and cardiovascular inflammation, a strategy of lowering interleukin-6 levels with ziltivekimab did not result in a lower risk of cardiovascular events than placebo. (Funded by Novo Nordisk; ZEUS ClinicalTrials.gov number, NCT05021835.).
Study context
- Population
- Adults with established atherosclerotic cardiovascular disease, chronic kidney disease, and cardiovascular inflammation (high-sensitivity CRP level of ≥2 mg per liter)
- Participants
- 6,376 adults
- Comparison
- Ziltivekimab vs placebo
- Ziltivekimabn = 3,184
- Placebon = 3,192reference
- Primary endpoint
- 3-point major adverse cardiovascular event (MACE):
- Death from cardiovascular causes
- Nonfatal myocardial infarction
- Nonfatal stroke
- Follow-up
- Median 33 months
Methodological details1:1 randomization
- 1:1 randomization
Primary result
As reported in the abstract
3-point MACE (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke)
Ziltivekimabvs placebo
HR 0.99 (95% CI 0.88–1.11); P = 0.84
Further findings
| Outcome | Estimate |
|---|---|
| Between-group difference in median percent change in inflammatory biomarkers · 24 monthsZiltivekimab vs placebo | difference in median percent change, free interleukin-6 −76 percentage points |
| Between-group difference in median percent change in inflammatory biomarkers · 24 monthsZiltivekimab vs placebo | difference in median percent change, high-sensitivity CRP −64 percentage points |
Baseline characteristics
- Mean age
- 69.4 years
- Women
- 27.5%
Safety
Serious adverse events
Serious infections
Original publication
Interleukin-6 Inhibition with Ziltivekimab for Atherosclerotic Disease. N Engl J Med. Published 7 November 2026. doi:10. 1056/ nejmoa2612126
Composed by AI from the published abstract and checked against it. How Briefs are made →